Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1Journal of the American Society of Nephrology.  30:2017-2026. 2019
2019 Second-Chance Placement of Hemodialysis Patients After Involuntary Discharge for Disruptive BehaviorAmerican Journal of Kidney Diseases.  74:544-548. 2019
2019 Description of 5 Novel SLC34A3/NPT2c Mutations Causing Hereditary Hypophosphatemic Rickets With HypercalciuriaKidney International Reports.  4:1179-1186. 2019
2019 Rituximab or cyclosporine in the treatment of membranous nephropathyNew England Journal of Medicine.  381:36-46. 2019
2019 Health-related quality of life in glomerular diseaseKidney International.  95:1209-1224. 2019
2019 A novel fluorescent clinical method to rapidly quantify plasma volumeCardioRenal Medicine.  9:168-179. 2019
2019 Confidence in Women's Health: A Cross Border Survey of Adult Nephrologists.Journal of Clinical Medicine.  8. 2019
2019 CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular DiseaseAmerican Journal of Kidney Diseases.  73:218-229. 2019
2019 Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney DiseaseCardioRenal Medicine2019
2019 Renal Complications in Pregnancy Preceding Glomerulonephropathy DiagnosisKidney International Reports.  4:159-162. 2019
2019 The emerging role of complement proteins as a target for therapy of IgA nephropathyFrontiers in Immunology.  10. 2019
2018 Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN StudyKidney International Reports.  3:1373-1384. 2018
2018 Prognostic value of myocardial perfusion imaging performed pre-renal transplantation: post-transplantation follow-up and outcomesEuropean Journal of Nuclear Medicine.  45:1998-2008. 2018
2018 Secondary IgA nephropathyKidney International.  94:674-681. 2018
2018 Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patientsBioTechniques.  65:71-77. 2018
2018 A novel method for rapid bedside measurement of GFRJournal of the American Society of Nephrology.  29:1609-1613. 2018
2018 Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathyPLoS ONE.  13. 2018
2017 Prognostic value of silent myocardial infarction in patients with chronic kidney disease being evaluated for kidney transplantationInternational Journal of Cardiology.  249:377-382. 2017
2016 The origin and activities of IgA1-containing immune complexes in IGA nephropathyFrontiers in Immunology.  7. 2016
2015 Migrated intra-jejunal peritoneal dialysis catheterKidney International.  88:1457. 2015
2015 Oral anticoagulants and risk of nephropathyDrug Safety.  38:527-533. 2015
2015 New Insights into the Pathogenesis of IgA Nephropathy.Kidney Diseases.  1:8-18. 2015
2015 Screening for Coronary Artery Disease in Kidney Transplant CandidatesJournal of Nuclear Cardiology.  22:297-300. 2015
2015 A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)Nephron.  130:159-168. 2015
2015 Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trialCirculation.  132:27-39. 2015
2015 The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trialClinical Journal of the American Society of Nephrology.  10:791-799. 2015
2014 Dietary patterns and risk of death and progression to ESRD in individuals with CKD: A cohort studyAmerican Journal of Kidney Diseases.  64:204-213. 2014
2014 The interdisciplinary team: The whole is larger than the partsAdvances in Renal Replacement Therapy.  21:333-337. 2014
2013 Renovascular hypertension associated with pseudoaneurysm following blunt traumaAmerican Journal of Kidney Diseases.  62:839-843. 2013
2013 Bullous Lesions After Use of a Commercial Therapeutic Hypothermia Temperature Management System: A Possible Burn Injury?Therapeutic Hypothermia and Temperature Management.  3:147-150. 2013
2013 Association between urinary albumin excretion and coronary heart disease in black vs white adultsJournal of the American Medical Association.  310:706-713. 2013
2013 Cardiovascular risk factors in CKD associate with both ESRD and mortalityJournal of the American Society of Nephrology.  24:1159-1165. 2013
2013 Cardioprotective medication use and risk factor control among US adults with unrecognized myocardial infarction: The REasons for geographic and racial differences in stroke (REGARDS) studyVascular Health and Risk Management.  9:47-55. 2013
2013 Association of duration of residence in the southeastern United States with chronic kidney disease may differ by race: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort studyInternational Journal of Health Geographics.  12. 2013
2013 Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseNew England Journal of Medicine.  369:2492-2503. 2013
2012 Racial differences in albuminuria, kidney function, and risk of strokeNeurology.  79:1686-1692. 2012
2012 Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney diseaseNephrology Dialysis Transplantation.  27:3482-3488. 2012
2012 Kidney disease education one year after the medicare improvement of patients and providers act: A survey of US nephrology practicesAmerican Journal of Kidney Diseases.  59:892-894. 2012
2011 Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortalityClinical Journal of the American Society of Nephrology.  6:2200-2207. 2011
2011 Warfarin-related nephropathy: Another newly recognized complication of an old drugKidney International.  80:131-133. 2011
2009 Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysisClinical Journal of the American Society of Nephrology.  4:560-566. 2009
2008 Gadolinium nephrotoxicity: Case report of a rare entity and review of the literatureClinical Nephrology.  70:518-522. 2008
2008 Gadolinium nephrotoxicity: case report of a rare entity and review of the literature.Clinical Nephrology.  70:518-522. 2008
2008 Treatment of autosomal dominant polycystic kidney disease (ADPKD): The new horizon for children with ADPKDPediatric Nephrology.  23:1029-1036. 2008
2004 Medullary cystic kidney disease type 2 [1] (multiple letters)American Journal of Kidney Diseases.  43:1142-1143. 2004
2003 Cystic and Inherited Kidney DiseasesAmerican Journal of Kidney Diseases.  42:1305-1317. 2003

Chapter

Year Title Altmetric
2013 Polycystic and other cystic kidney diseases.  362-370. 2013

Research Overview

  • IgA nephropathy
    Glomerulonephritis
    ADPKD
  • Principal Investigator On

  • Private Grant  awarded by CALLIDITAS THERAPEUTICS AB 2019 - 2026
  • Private Grant  awarded by REATA PHARMACEUTICALS 2019 - 2024
  • Private Grant  awarded by RETROPHIN, INC. 2019 - 2024
  • Private Grant  awarded by ACHILLION PHARMACEUTICALS INC 2018 - 2022
  • Private Grant  awarded by REATA PHARMACEUTICALS 2018 - 2022
  • Private Grant  awarded by REATA PHARMACEUTICALS 2019 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2019 - 2021
  • Private Grant  awarded by REATA PHARMACEUTICALS 2017 - 2020
  • Private Grant  awarded by ABBVIE INC 2015 - 2018
  • A Randomized Controlled Trial of Rituximub versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)  awarded by MAYO CLINIC 2013 - 2018
  • Private Grant  awarded by FAST BIOMEDICAL 2017
  • Private Grant  awarded by NEPHROGENEX, INC. 2015 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by FAST BIOMEDICAL 2013 - 2014
  • Private Grant  awarded by REATA PHARMACEUTICALS 2011 - 2013
  • Private Grant  awarded by REATA PHARMACEUTICALS 2012
  • Private Grant  awarded by AMGEN, INC. 2007 - 2012
  • Private Grant  awarded by REATA PHARMACEUTICALS 2009 - 2010
  • Education And Training

  • Doctor of Medicine, 1997
  • St. Louis University Hospitals, Internship 1999
  • American University of Beirut Medical Center, Internship 1998
  • Emory University Hospital Systems, Residency 2001
  • St. Louis University Hospitals, Residency 2000
  • Emory University Hospital Systems, Postdoctoral Fellowship 2005
  • Full Name

  • Dana Rizk